New Hope for Hair Loss Treatment? 🚨 'Veradermics' Oral Hair Loss Drug 'VDPHL01' Shows Breakthrough Hair Growth in Phase 2 Clinical Trial! (Overcoming Minoxidil Limitations)
New hope has emerged for those suffering from hair loss. The oral hair loss drug 'VDPHL01', which is expected to overcome the limitations of 'Minoxidil' (the only known drug effective for hair growth) and provide even more powerful and sustained effects, has announced positive results in its Phase 2 clinical trial. 'Veradermics'' innovative technology has given rise to VDPHL01, which is expected to open new horizons in hair loss treatment for both men and women. Let's delve into what makes it so special!
1. Limitations of Existing Minoxidil: Short In-Vivo Half-Life and Side Effects
Minoxidil is known as the only ingredient that promotes hair growth for both men and women. However, commercially available oral Minoxidil was originally developed as a hypertension medication and is not optimized for hair loss treatment.
- Short In-Vivo Half-Life: Drug levels spike sharply immediately after administration but are mostly expelled from the body within about 2 hours, limiting the time available to stimulate hair growth.
- Cardiac Side Effects: This rapid increase in concentration can potentially exceed the 'cardiac activity threshold,' possibly leading to cardiac toxicity.
- Inconvenience of Topical Minoxidil: Topical Minoxidil 5%, such as Rogaine, offers limited efficacy, and approximately 90% of patients discontinue use due to its messy and inconvenient application.
2. The Innovation of 'VDPHL01': Minoxidil that Stays in Hair Follicles for an 'Extended Period'
Veradermics developed 'VDPHL01' using its proprietary 'Extended-Release Technology' to overcome the limitations of existing Minoxidil.
- Optimized for Hair Loss Treatment: VDPHL01 is an oral Minoxidil specifically designed for hair regrowth from the outset.
- Extended Action in Hair Follicles: The drug is designed to remain and act in hair follicles for an extended period, promoting consistent and intense hair growth.
- Reduced Risk of Cardiac Side Effects: By preventing sharp spikes in drug concentration, it avoids blood levels above the 'cardiac activity threshold,' thus having the potential to lower the risk of cardiac-related side effects.
3. VDPHL01 Phase 2 Clinical Trial Results: Groundbreaking Hair Growth Effects!
Highly encouraging results were announced from the VDPHL01 Phase 2 clinical trial conducted on participants with male-pattern hair loss.
- Participants: 21 male participants in the Phase 2 clinical trial.
- Dosage and Duration: VDPHL01 8.5mg administered twice daily (BID) for 4 months.
- Key Results:
- Increase in Non-Vellus Hair Count: Participants showed an average increase of 47.3 non-vellus hairs/cm2 (thick, pigmented hairs). This is a highly significant number.
- Improved Hair Coverage: 90.5% of male patients reported 'improved' or 'much improved' hair coverage.
- Increased Satisfaction: 95.0% of patients responded that their satisfaction with hair coverage increased.
- Safety: To date, no Serious Adverse Events related to VDPHL01 have been reported, and no cardiac-related side effects were observed.
4. Future Plans: Phase 3 Clinical Trials Currently Underway, Targeting $30 Billion in Sales by 2028
Based on the successful Phase 2 clinical trial results of VDPHL01, Veradermics is actively conducting Phase 3 clinical trials targeting both men and women.
- Secured Substantial Funding: Over $150 million (approximately 200 billion KRW) in Series C funding has been secured for Phase 3 clinical trials, accelerating its successful development.
- Commercial Goal: Veradermics aims for $30 billion (approximately 40 trillion KRW) in sales by 2028, indicating the company's high expectations for VDPHL01.
- Hope for Female Hair Loss Treatment: If approved, VDPHL01 is expected to become the 'first and only extended-release oral Minoxidil' in the field of female-pattern hair loss, which has seen no new prescription treatments for the past 30 years and no FDA-approved oral treatments.
'VDPHL01' to Change the Paradigm of Hair Loss Treatment, the Future Looks Promising!
Designed to overcome Minoxidil's limitations and act in hair follicles for an extended period, Veradermics' 'VDPHL01' has demonstrated groundbreaking hair growth effects and high patient satisfaction in its Phase 2 clinical trials, offering great hope to those suffering from hair loss. Global attention is focused on the results of VDPHL01's Phase 3 clinical trials and its future commercialization, as this non-hormonal oral treatment is set to provide new treatment options for both men and women.
#HairLoss #HairLossTreatment #HairLossDrug #VDPHL01 #Veradermics #Minoxidil #OralHairLossDrug #Phase2ClinicalTrial #Phase3ClinicalTrial #HairGrowth #FemaleHairLoss #MaleHairLoss #HairLossSolution #HairLossMedication #HairLossResearch #NewHairLossDrug #HealthInformation #PharmaceuticalBio #Hairline #HairCare
